In fact, studies have shown that CD8+ T cell reactivity against melanocyte-specific differentiation antigens was the dominant response, whereas CD8+ reactivity against tumor-specific mutations was infrequent [27–30]. This evidence concerns the gene CD8A and neoplasm.